keyword
MENU ▼
Read by QxMD icon Read
search

peripheral blood stem cell harvest

keyword
https://www.readbyqxmd.com/read/29766024/integrating-hdad5-35-vectors-as-a-new-platform-for-hsc-gene-therapy-of-hemoglobinopathies
#1
Chang Li, Nikoletta Psatha, Hongjie Wang, Manvendra Singh, Himanshu Bhusan Samal, Wenli Zhang, Anja Ehrhardt, Zsuzsanna Izsvák, Thalia Papayannopoulou, André Lieber
We generated an integrating, CD46-targeted, helper-dependent adenovirus HDAd5/35++ vector system for hematopoietic stem cell (HSC) gene therapy. The ∼12-kb transgene cassette included a β-globin locus control region (LCR)/promoter driven human γ-globin gene and an elongation factor alpha-1 (EF1α)-mgmtP140K expression cassette, which allows for drug-controlled increase of γ-globin-expressing erythrocytes. We transduced bone marrow lineage-depleted cells from human CD46-transgenic mice and transplanted them into lethally irradiated recipients...
June 15, 2018: Molecular Therapy. Methods & Clinical Development
https://www.readbyqxmd.com/read/29753677/multicenter-phase-1-2-application-of-adenovirus-specific-t-cells-in-high-risk-pediatric-patients-after-allogeneic-stem-cell-transplantation
#2
Winnie Ip, Juliana M F Silva, Hubert Gaspar, Arindam Mitra, Shreenal Patel, Kanchan Rao, Robert Chiesa, Persis Amrolia, Kimberly Gilmour, Gul Ahsan, Mary Slatter, Andrew R Gennery, Robert F Wynn, Paul Veys, Waseem Qasim
BACKGROUND: Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity. METHOD: This study was an open-label phase 1/2 study to investigate the feasibility of generating donor-derived ADV-specific T cells (Cytovir ADV, Cell Medica) and to assess the safety of pre-emptive administration of ADV-specific T cells in high-risk pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) to treat adenoviremia...
May 9, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29622882/peripheral-blood-monocyte-count-is-a-predictor-of-successful-peripheral-blood-stem-cell-harvest-after-chemo-mobilization-in-patients-with-malignant-lymphoma
#3
Yoshimi Ishii, Shin Fujisawa, Chika Nigauri, Taiki Ando, Taisei Suzuki, Eriko Ogusa, Kazuho Miyashita, Kenji Motohashi, Hideaki Nakajima
No abstract text is available yet for this article.
April 2018: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/29605509/the-effects-of-lower-cd34-yields-after-lowe-dose-g-csf-induction-on-long-term-autologous-stem-cell-transplantation-outcome-a-single-center-study
#4
Mohammad Vaezi, Mohammad Shakouri, Maryam Souri, Mohammad Amin Setaredan, Seyed Asadollah Mossavi, Saeed Mohammadi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood stem cells performs in different ways among transplantation centers. Since the Effects of lower CD34+ cells dose after low dose G-CSF induction on autologous stem cell transplantation outcomes are not studied much, so this study was performed for this purpose. 735 autologous stem cell transplanted patients with diagnoses of multiple myeloma (n = 330), Hodgkin lymphoma (n = 200), non-Hodgkin lymphoma (n = 129), acute myeloid leukemia (n = 54) and solid tumors (n = 22) were retrospectively evaluated...
March 23, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29576502/the-healthy-donor-profile-of-immunoregulatory-soluble-mediators-is-altered-by-stem-cell-mobilization-and-apheresis
#5
Guro Kristin Melve, Elisabeth Ersvaer, Kristin Paulsen Rye, Aymen Bushra Ahmed, Einar K Kristoffersen, Tor Hervig, Håkon Reikvam, Kimberley Joanne Hatfield, Øystein Bruserud
BACKGROUND: Peripheral blood stem cells from healthy donors mobilized by granulocyte colony-stimulating factor (G-CSF) and thereafter harvested by leukapheresis are commonly used for allogeneic stem cell transplantation. METHODS: Plasma levels of 38 soluble mediators (cytokines, soluble adhesion molecules, proteases, protease inhibitors) were analyzed in samples derived from healthy stem cell donors before G-CSF treatment and after 4 days, both immediately before and after leukapheresis...
March 22, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29555414/medical-and-ethical-considerations-on-hematopoietic-stem-cells-mobilization-for-healthy-donors
#6
V Moalic-Allain
Hematopoietic stem cell transplantation is a common procedure potentially beneficial to many individuals with cancer, hematological, or inherited disorders, and has highlighted the need of related or unrelated donors to perform allograft. Donation of hematopoietic stem cells, either through bone marrow harvest or peripheral blood stem cell collection, is well-established and widespread. Over the past two decades, the peripheral blood stem cell collection by aphaeresis has become the main source of hematopoietic stem cells for transplantation, due to faster engraftment and practicability and lower risk of relapse for high-risk patients...
March 16, 2018: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
https://www.readbyqxmd.com/read/29532760/efficacy-and-safety-of-autologous-cell-based-therapy-in-patients-with-no-option-critical-limb-ischaemia-a-meta-analysis
#7
Fadilah S Abdul Wahid, Nor Azimah Ismail, Wan Fariza Wan Jamaluddin, Nor Asiah Muhamad, Mohamad Mohamad Azim Mohamad Idris, Nai Ming Lai
BACKGROUND: Revascularisation therapy is the curent gold standard of care for critical limb ischaemia (CLI), although a significant proportion of patients with CLI either are not fit for or do not respond well to this procedure. Recently, novel angiogeneic therapies such as the use of autologous cell-based therapy (CBT) have been examined, but the results of individual trials were inconsistent. OBJECTIVE: To pool all published studies that compared the safety and efficacy of autologous CBT derived from different sources and phenotypes with non cell-based therapy (NCT) in CLI patients...
March 13, 2018: Current Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29515065/-efficacy-and-safety-of-biosimilar-filgrastim-for-autologous-peripheral-blood-stem-cell-harvest-and-transplantation-a-single-institutional-retrospective-analysis
#8
Masaki Iino, Takeo Yamamoto
Three biosimilar filgrastim products are currently available in Japan. Among these, the safety and efficacy of two imported drugs for autologous peripheral blood stem cell harvest (autoPBSCH) and autologous peripheral blood stem cell transplantation (autoPBSCT) have been studied widely; however, evidence of the safety and efficacy of domestically manufactured filgrastim is limited. Therefore, we compared the efficacy and safety of domestic biosimilar filgrastim (BF1, n=23) with those of originator filgrastim (OF, n=21) for autoPBSCH and autoPBSCT...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29498177/significant-correlation-between-peripheral-blood-cd34-cell-count-in-children-prior-to-aphaeresis-and-cd34-cell-yield-following-aphaeresis-a-single-center-experience
#9
Hila Rosenfeld-Keidar, Rinat Eshel, Aviva Pinhasov, Menachem Bitan, Sabina Edelman, Marcela Broitman, Rina Dvir, Efraim Sadot, Dror Levin, Michal Manisterski, Sivan Berger-Achituv, Ronit Elhasid
Numerous adults' studies demonstrated that preaphaeresis CD34+ cells significantly correlate with the number of CD34+ cells collected by the aphaeresis procedure. Equivalent studies in children are scarce. We studied retrospectively 92 aphaeresis procedures performed following chemotherapy (44) or in steady state (48) in 60 pediatric patients (40 males, 20 females), median age of 7.5 years. Aphaeresis procedures were performed using a SPECTRA Optica (TERUMOBCT) continuous flow cell separator. CD34+ cell concentrations were assessed using flow cytometry...
May 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29475092/the-impact-of-donor-characteristics-on-the-invariant-natural-killer-t-cells-of-granulocyte-colony-stimulating-factor-mobilized-marrow-grafts-and-peripheral-blood-grafts
#10
Yan Hong, Xiang-Yu Zhao, Xing-Xing Yu, Zhi-Lei Bian, Ying-Jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Su Zhao
INTRODUCTION: Invariant natural killer T cells (iNKTs) are a rare but vital subset of immunomodulatory T cells and play an important role in allogeneic hematopoietic stem cell trans-plantation (HSCT). The association of donor characteristics with the number and frequency of the iNKTs subsets in allografts remains poorly understood. In this paper, we prospectively investigate the association of donor characteristics with iNKTs dose and frequency in granulocyte-colony-stimulating factor (G-CSF) mobilized marrow and peripheral blood harvests...
February 21, 2018: Transplant Immunology
https://www.readbyqxmd.com/read/29416004/regenerative-potential-of-tonsil-mesenchymal-stem-cells-on-surgical-cutaneous-defect
#11
Sung-Chan Shin, Yoojin Seo, Hee Young Park, Da-Woon Jung, Tae-Hoon Shin, Haejin Son, Young Keum Kim, Jin-Choon Lee, Eui-Suk Sung, Jeon Yeob Jang, Hyung-Sik Kim, Byung-Joo Lee
As tissue engineering and regenerative medicine have evolved recently, stem cell therapy has been investigated in the field of impaired wound healing. Several studies have reported that mesenchymal stem cells derived from various tissues including bone marrow and adipose tissue can exert the regenerative efficacy in the wound healing. Previously, we have demonstrated the isolation and characterization of tonsil-derived mesenchymal stem cells (TMSCs) with excellent proliferative property. In the present study, we aimed to evaluate the regenerative efficacy of TMSCs in the wound healing process...
February 7, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29404376/successful-use-of-intravenous-immunoglobulin-g-to-treat-refractory-heparin-induced-thrombocytopenia-with-thrombosis-complicating-peripheral-blood-stem-cell-harvest
#12
Devon S McKenzie, Josephine Anuforo, Jennah Morgan, Elvira Neculiseanu
Heparin-induced thrombocytopenia is a well-known, life-threatening complication that occurs in 5% of patients exposed to heparin. It causes thrombocytopenia in roughly 85% to 90% of affected individuals, with expected recovery in approximately 4 to 10 days following heparin withdrawal. However, there is an entity known as refractory heparin-induced thrombocytopenia with thrombosis in which patients have prolonged thrombocytopenia, refractory to the current standard of care. We present one such case of a 48-year-old male with R-ISS (Revised International Staging System) stage II kappa light chain multiple myeloma in stringent complete response status postinduction therapy...
January 2018: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/29398647/pegylated-filgrastim-versus-filgrastim-for-stem-cell-mobilization-in-multiple-myeloma-after-novel-agent-induction
#13
Muhammad Bilal Abid, Sanjay De Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Li Mei Poon, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan
BACKGROUND: The current standard of care for transplant-eligible myeloma patients is novel agent-based induction, followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSCs) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness...
March 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29390394/recombinant-human-thrombopoietin-improves-the-efficacy-of-intermediate-dose-cyclophosphamide-plus-granulocyte-colony-stimulating-factor-in-mobilizing-peripheral-blood-stem-cells-in-patients-with-multiple-myeloma-a-cohort-study
#14
Guorong Wang, Wenming Chen, Yin Wu, Yanchen Li, Yun Leng, Aijun Liu
The combination of intermediate-dose cyclophosphamide (ID-CTX) and granulocyte colony-stimulating factor (G-CSF) fails to mobilize peripheral blood stem cells (PBSCs) in approximately 20% of treated patients with multiple myeloma (MM).In this cohort study, patients with MM underwent PBSC mobilization with either an ID-CTX plus G-CSF plus recombinant human thrombopoietin (rhTPO) regimen (72 patients; TPO group), or an ID-CTX plus G-CSF regimen (70 patients; non-TPO group).In the TPO group, the median CD34+ harvest was 5...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29388164/improved-progression-free-and-event-free-survival-in-myeloma-patients-undergoing-pbsch-receiving-a-cyclophosphamide-g-csf-regimen-than-g-csf-alone
#15
Akira Tanimura, Risen Hirai, Miki Nakamura, Masataka Takeshita, Shotaro Hagiwara, Akiyoshi Miwa
Two regimens are commonly used for peripheral blood hematopoietic stem cell harvesting (PBSCH) in multiple myeloma: high-dose cyclophosphamide (HD-CY) + granulocyte-colony stimulating factor (G-CSF), and G-CSF alone. The objective of the present study was to evaluate the anti-myeloma effect of the PBSCH regimen including HD-CY. We retrospectively assessed harvesting efficiency, complications, and anti-myeloma effects in 115 patients receiving HD-CY + G-CSF (HD-CY group) and 32 patients receiving G-CSF alone (G-alone group)...
May 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29384978/efficacy-and-safety-of-autologous-peripheral-blood-stem-cell-transplantation-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-a-study-protocol-for-a-multicenter-exploratory-prospective-study-auto-ph17-study
#16
MULTICENTER STUDY
Satoshi Nishiwaki, Isamu Sugiura, Yasuhiko Miyata, Shigeki Saito, Masashi Sawa, Tetsuya Nishida, Koichi Miyamura, Yachiyo Kuwatsuka, Akio Kohno, Masaaki Yuge, Masanobu Kasai, Hiroatsu Iida, Shingo Kurahashi, Masahide Osaki, Tatsunori Goto, Seitaro Terakura, Makoto Murata, Hiroyoshi Nishikawa, Hitoshi Kiyoi
INTRODUCTION: The prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) has been dramatically improved since the introduction of tyrosine kinase inhibitors (TKIs). Although allogeneic hematopoietic cell transplantation (allo-HCT) is a major treatment option, the role of autologous peripheral blood stem cell transplantation (auto-PBSCT) has been reconsidered, especially in patients who achieved early molecular remission. METHODS AND ANALYSIS: This is a multicenter exploratory study for Ph + ALL patients aged between 55 and 70 years who achieved complete molecular remission within 3 cycles of chemotherapy...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29350425/the-impact-of-preapheresis-white-blood-cell-count-on-autologous-peripheral-blood-stem-cell-collection-efficiency-and-hsc-infusion-side-effect-rate
#17
Araci M Sakashita, Andrea T Kondo, Ana Paula H Yokoyama, Sanny M C Lira, Carolina B Bub, Aline M Souza, Andrea N F Cipolletta, Kelen C Alvarez, Nelson Hamerschlak, Jose M Kutner, Carlos S Chiattone
BACKGROUND: Autologous peripheral blood hematopoietic stem cell (PBSC) collection efficiency (CE) is reportedly affected by the patient's blood properties; however, studies to identify factors correlated with CE have shown inconsistent results. Additionally, variables such as stem cell graft granulocyte content and patient age, sex, and underlying disease, may be associated with hematopietic stem cell (HSC) infusion-related adverse reactions. In this study, we evaluated the correlation of preleukapheresis PB granulocyte count and PBSC harvest variables with CD34+ collection yield and efficiency, and thawed HSC infusion side effect occurrence...
January 19, 2018: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/29277910/associated-factors-of-umbilical-cord-blood-collection-quality
#18
REVIEW
Lionel Faivre, Chloé Couzin, Hélène Boucher, Thomas Domet, André Desproges, Olivier Sibony, Marina Bechard, Valérie Vanneaux, Jérôme Larghero, Audrey Cras
After 30 years of hematopoietic stem cell use for various indications, umbilical cord blood is considered as an established source of cells with marrow and postmobilization peripheral blood. The limited number of cells still remains a problematic element restricting their use, especially in adults who require to be grafted with a higher cell number. Improving the quality of harvested cord blood, at least in terms of volume and amount of cells, is essential to decrease the number of discarded units. In this review, we examine several variables related to parturient, pregnancy, labor, delivery, collection, the newborn, umbilical cord, and placenta...
February 2018: Transfusion
https://www.readbyqxmd.com/read/29212970/-prior-harvesting-and-cryopreservation-of-peripheral-blood-stem-cells-from-related-donors-current-situations-in-japan
#19
Takeshi Kobayashi, Kazuteru Ohashi, Kyoko Haraguchi, Yoshiki Okuyama, Masayuki Hino, Junji Tanaka, Yasunori Ueda, Tetsuya Nishida, Yoshiko Atsuta, Minoko Takanashi, Minako Iida, Kazuo Muroi, Hiromasa Yabe, Koichi Miyamura
Although peripheral blood stem cell (PBSC) transplantations in an unrelated transplant setting have been performed since 2010, prior harvesting and cryopreservation of PBSCs from unrelated donors has not been approved in Japan. There are no restrictions with regard to related donors. Therefore, in April 2015, we conducted a nationwide survey and obtained written answers from 123 transplant hospitals throughout Japan. Our survey revealed that as much as 81.3% of transplant hospitals routinely perform prior harvesting and cryopreservation of PBSCs from related donors and that both cell processing and quality management of cryopreserved products have been appropriately conducted in line with domestic guidelines, although post-thaw quality control and storage period setting require further improvements...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29168461/study-of-stem-cell-homing-self-renewal-marker-gene-profile-of-ex-vivo-expanded-human-cd34-cells-manipulated-with-a-mixture-of-cytokines-stromal-cell-derived-factor-1
#20
Jyoti Kode, Navin Khattry, Ashish Bakshi, Vasanti Amrutkar, Bhausaheb Bagal, Rohini Karandikar, Pallavi Rane, Nobutaka Fujii, Shubhada Chiplunkar
BACKGROUND & OBJECTIVES: Next generation transplantation medicine aims to develop stimulating cocktail for increased ex vivo expansion of primitive hematopoietic stem and progenitor cells (HSPC). The present study was done to evaluate the cocktail GF (Thrombopoietin + Stem Cell factor + Flt3-ligand) and homing-defining molecule Stromal cell-derived factor 1 (SDF1) for HSPC ex vivo expansion. METHODS: Peripheral blood stem cell (n=74) harvests were analysed for CD34hiCD45lo HSPC...
July 2017: Indian Journal of Medical Research
keyword
keyword
76725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"